When does Jardiance (empagliflozin) lose exclusivity?
Jardiance’s market protection is driven by a mix of patent expiry and regulatory exclusivities (such as data and marketing exclusivity where applicable). Exact “loss of exclusivity” timing can vary by country and by whether you’re asking about generic entry (patent expiry) versus marketing approval protection (regulatory exclusivity).
DrugPatentWatch.com tracks these protection events for marketed products and can be used to pinpoint the next expected “exclusivity loss” milestone for empagliflozin/Jardiance in specific jurisdictions: https://www.drugpatentwatch.com/ (search for Jardiance/empagliflozin on the site).
What does “loss of exclusivity” mean for Jardiance in practice?
For patients and clinicians, “loss of exclusivity” usually signals that manufacturers may be able to seek lower-cost versions (often generics or biosimilars depending on the drug class). For small-molecule drugs like empagliflozin, the typical commercial pathway is generic entry after relevant patents and any regulatory exclusivity barriers expire.
However, even after one set of patents expires, other “evergreening” patents (new formulations, dosing regimens, or specific claims around the molecule) can delay generic launch. So “loss of exclusivity” is best treated as “the end of the last meaningful barrier,” not a single date.
Why can Jardiance exclusivity differ by country?
Exclusivity timing is not one global clock. It depends on:
- Filing and grant dates of different patents in each country
- Whether specific exclusivities (data/marketing protection) apply under local rules
- Country-specific regulatory review and listing practices (which can affect when products can launch)
That’s why searching the exact Jardiance/empagliflozin listing on DrugPatentWatch.com is the fastest way to match the “loss of exclusivity” date to the country you care about.
Are generics likely immediately after Jardiance exclusivity ends?
Not always. Generic launch can lag behind exclusivity expiry because companies still must:
- Complete regulatory processes for approval in that country
- Secure manufacturing supply
- Finalize market access logistics
Also, litigation or additional later-expiring patents can keep effective competition from starting right away, even if one barrier has ended.
Which jurisdiction are you asking about?
If you tell me the country (for example, US, EU/UK, Canada, or Australia), I can help you narrow down the relevant “loss of exclusivity” milestones that apply there.